AmyriAD – Looking Beyond Amyloid for Alzheimer’s Disease: Combination Therapy, a Strategy Long Overdue
|DATE:||September 30, 2022|
|TIME:||11:15 AM EDT|
About The Event
AmyriAD Therapeutics invites you to a webinar event that will feature a discussion between Key Opinion Leaders (KOLs) Serge Gauthier, CM, MD, FRCPC (Clinical Trials in Alzheimer’s Disease – EU/US Task Force; Former Director, Alzheimer Disease and Related Disorders Research Unit, McGill Center for Studies in Aging, Douglas Research Centre, McGill University) and Howard M Fillit, MD (Co-Founder and Chief Science Office of the Alzheimer’s Drug Discovery Foundation).
Throughout the past two decades, an intense focus has been on modification of Alzheimer’s Disease (AD). However, very little attention has been given to developing therapies for effective management of the core symptoms of the disease: declining cognition and loss of independent function. This KOL presentation between two world-renowned leaders in AD patient management will discuss investigational strategies designed to improve these symptoms in patients at all stages of AD, while also benefitting caregivers and our overall healthcare system.
About AmyriAD Therapeutics
AmyriAD is a late-clinical-stage pharmaceutical company developing innovative treatments for Alzheimer’s disease. AmyriAD’s lead candidate, AD101, is an acetylcholine release agent that in combination therapy with donepezil (Aricept®) was well-tolerated and demonstrated improvement in global function and cognition in a randomized, double-blind, placebo-controlled, Phase 2 proof-of-concept trial.